# Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma

> **NCT06199271** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhongzheng Xiang** · enrollment: 30 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Adebrelimab and dalpiciclib

## Key facts

- **NCT ID:** NCT06199271
- **Lead sponsor:** Zhongzheng Xiang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-01-31
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06199271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06199271, "Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06199271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*